Paratek Pharmaceuticals Completes Merger With Transcept

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals

BOSTON, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ) and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) (through October 30) today announced the two companies have completed their merger effective as of October 30, 2014.

Immediately prior to the merger, Paratek received gross proceeds of $93 million in new investment from a combination of certain current and new investors in Paratek, including Abingworth LLP, Aisling Capital, The Baupost Group, HBM Healthcare Investments, Interwest Ventures, Omega Funds, Roumell Asset Management and other highly regarded institutional investors. Together with approximately $14 million in available, pre-merger cash on Transcept's balance sheet, the combined company has approximately $108 million in cash available before the payment of transaction and other fees.

Prior to the merger, Transcept effected a 12-1 reverse stock split of its outstanding common stock. As a result of the reverse stock split, every 12 shares of Transcept common stock outstanding immediately prior to the merger were combined and reclassified into one share of Transcept common stock. No fractional shares are being issued in connection with the reverse stock split. Instead, cash, based on the closing price of Transcept common stock on The NASDAQ Global Market on October 30, 2014, will be issued in lieu of fractions of shares.

The holders of shares of Paratek common stock outstanding immediately prior to the merger received 0.0675 shares of Transcept common stock in exchange for each share of Paratek common stock in the merger. The exchange ratio reflects the 12-1 reverse stock split. Following the $93 million financing, the reverse stock split and the merger, the combined company has approximately 14.4 million shares outstanding.

Also in connection with the merger, Transcept changed its name to Paratek Pharmaceuticals, Inc. The combined company will commence trading as of October 31, 2014 on The NASDAQ Global Market under the symbol "PRTK".

The combined company will operate under the leadership of Michael F. Bigham, Chairman and Chief Executive Officer. The combined company's board of directors is comprised of representatives from the former Paratek board of directors, a representative from the former Transcept board of directors and two new directors. In addition to Michael F. Bigham, the directors are Evan Loh, M.D., Richard J. Lim, Thomas J. Dietz, Ph.D., Jeffrey Stein, Ph.D., and Robert Radie.

"We are very pleased to complete this merger, which marks a significant milestone for Paratek. We are transitioning from a private company to a publicly-traded company through this merger, and significantly increasing our financial resources," said Michael F. Bigham. "These funds will enable us to develop and prepare for the potential commercialization of our phase 3-ready drug candidates, with a key focus on omadacycline for serious community acquired infections."

Evan Loh, President and Chief Medical Officer, commented "Omadacycline is a new, broad-spectrum antibiotic we are developing for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern. We believe it has the potential to become the primary antibiotic choice of physicians for the treatment of community-acquired bacterial infections. We expect that our special protocol assessment (SPA) agreements with the US Food and Drug Administration (FDA) for the phase 3 trial designs in acute bacterial skin and skin structure infections (ABSSSI) and community acquired bacterial pneumonia (CABP) will enable Paratek to initiate these trials in 2015, moving us one step closer to bringing this important medicine to the patients who need it."

About Omadacycline

Omadacycline is a new once daily intravenous and oral tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for patients suffering from serious community-acquired bacterial infections, such as ABSSSI, CABP and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Omadacycline was designed to provide broad spectrum activity, and possibly shorter hospital stays, by allowing for the completion of therapy at home with an oral formulation, thereby potentially positioning omadacycline to become the primary antibiotic choice of physicians for the treatment of serious community-acquired bacterial infections.

About Paratek

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

Paratek's second product candidate, WC 3035 (sarecycline), is a new tetracycline-derived compound, with dual narrow-spectrum antibacterial and potent anti-inflammatory activity, for the treatment of acne and rosacea in the community setting. Paratek has licensed rights to WC 3035 for the treatment of acne and rosacea in the United States to a subsidiary of Actavis (formerly Warner Chilcott), while retaining rights in the rest of the world. Actavis is responsible for the clinical development of WC 3035 for the treatment of acne in the United States. A phase 3 program in moderate-severe acne is expected to be initiated in 2014 for WC 3035.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives, intentions, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to the availability of cash for Paratek's future operations, Paratek's ability to develop its drug candidates for potential commercialization, the timing of the commencement of omadacycline phase 3 trials for ABSSSI and CABP, the potential for omadacycline to be successfully developed for use as a first-line empiric monotherapy for patients suffering from serious community-acquired bacterial infections, the potential of omadacycline to become the primary antibiotic choice of physicians for the treatment of serious community-acquired bacterial infections, including ABSSSI, CABP and UTI, the potential use and effectiveness of WC 3035 (sarecycline) for the treatment of acne and rosacea in the community setting, and the timing of the commencement of a phase 3 program in moderate-severe acne for WC 3035. Paratek may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Paratek makes, including the risks that Paratek's planned clinical trials may be prolonged or delayed requiring Paratek to incur additional costs; that Paratek's planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities; that Paratek's product candidates may have undesirable side effects which may delay or prevent marketing approval; that, even if approved by the FDA or non-U.S. regulatory authorities, Paratek's product candidates may not achieve broad market acceptance; and the risks described in the "Risk Factors" sections the Registration Statement on Form S-4 (file no. 333-298464) and of Paratek's periodic reports filed with the SEC. Paratek does not assume any obligation to update any forward-looking statements, except as required by law.

Paratek Pharmaceuticals, Inc. Evan Loh President and Chief Medical Officer (617) 275-0040 x223 Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 109

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 77

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 73

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 13

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 57

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 23

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 147

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 50

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading